Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > nosh

<< Previous

Bullboard Posts

Next >>

Post by Nick80on Jun 04, 2021 12:50pm

230 Views

Post# 33330474

nosh

Hi what are you guys think about:
https://www.avicennatherapeutics.com/technology

Would they be serious competition for ate 346, 352 or 340?

From my understanding their platform might outperform ATE's 340 drug if successful, however what about 346 and others?

Their nosh platform is in pre-clinical only meaning ate is very well advanced and derisked compared to them...

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario